ono pharmaceutical co ltd (4528) Details

Ono Pharmaceutical Co., Ltd. engages in the research, development, production, purchase, and sale of pharmaceuticals and diagnostic reagents in Japan. The company primarily focuses on prescription pharmaceuticals. Its products include Rivastach Patch for the treatment of alzheimer's disease; Glactiv tablets for the treatment of type II diabetes; Emend capsules for chemotherapy-induced nausea and vomiting; Recalbon tablets for osteoporosis; Staybla tablets for the treatment of overactive bladder; Opalmon tablets for peripheral circulatory disorder; and Onon capsules for bronchial asthma and allergic rhinitis. The company’s products also consists of Onon dry syrup for the treatment of bronchial asthma; Kinedak tablets for diabetic peripheral neuropathy; Foipan tablets for chronic pancreatitis and postoperative reflux esophagitis; Elaspol injection for acute lung injury associated with systemic inflammatory response syndrome; and Onoact injection for the treatment of tachyarrhythmia during or after operations. Its development pipeline through in-licensing with various drug and biopharmaceutical companies comprise ONO-7643/RC-1291, a compound for cancer anorexia/cachexia; ONO-2745/CNS-7056, a general anesthetic product; ONO-7746/NIP- 022, a therapeutic agent for thrombocytopenia; ONO-3849, a drug for the treatment of intractable constipation induced by narcotic analgesic; ONO-3951 for the treatment of diarrhea predominant irritable bowel syndrome; ONO-7057, a drug for the treatment of multiple myeloma; ONO-7056, a therapy drug for pancreatic cancer; and a liver cancer vaccine. The company has drug discovery strategic alliances with various biopharmaceuticals and research institutions, such as Array BioPharma Inc.; Locus Pharmaceuticals, Inc.; BioSeek LLC; Xention Limited; BioFocus; Evotec AG; Scil Proteins GmbH; and Receptos Inc. Ono Pharmaceutical Co., was founded in 1717 and is headquartered in Osaka, Japan.

ono pharmaceutical co ltd (4528) Top Compensated Officers